University of Rennes Reports Findings in Cancer (An algorithm for identifying chronic kidney disease in the French national health insurance claims database): Cancer

Information Technology Business Daily

2022 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Cancer is the subject of a report. According to news reporting originating from Rennes, France, by NewsRx correspondents, research stated, “Published algorithms for identifying chronic kidney disease in healthcare claims databases have poor performance except in patients with renal replacement therapy. We propose and describe an algorithm to identify all stage chronic kidney disease in a French healthcare claims databases and assessed its performance by using data from the Renal Epidemiology and Information Network registry and the French Childhood Cancer Survivor Study cohort.”

Our news editors obtained a quote from the research from the University of Rennes, “A group of experts met several times to define a list of items and combinations of items that could be related to chronic kidney disease. For the French Childhood Cancer Survivor Study cohort, information on confirmed chronic kidney disease cases extracted from medical records was considered the gold standard (KDIGO definition). Sensitivity, specificity, and positive and negative predictive value and kappa coefficients were estimated. The contribution of each component of the algorithm was assessed for 1 and 2 years before the start of renal replacement therapy for confirmed end-stage kidney disease in the Renal Epidemiology and Information Network registry. The algorithm’s sensitivity was 78%, specificity 97.4%, negative predictive value 98.4% and positive predictive value 68.7% in French Childhood Cancer Survivor Study cohort and the kappa coefficient was 0.79 for agreement with the gold standard. The algorithm 93.6% and 55.1% of confirmed incident end-stage kidney disease cases from the Renal Epidemiology and Information Network registry when considering 1 year and 2 years, respectively, before renal replacement therapy start. The algorithm showed good performance among younger patients and those with end-stage kidney disease in the twol last years prior to renal replacement therapy.”

According to the news editors, the research concluded: “Future research will address the ability of the algorithm to detect early chronic kidney disease stages and to classify the severity of chronic kidney disease.”

This research has been peer-reviewed.

For more information on this research see: An algorithm for identifying chronic kidney disease in the French national health insurance claims database. Nephrologie & Therapeutique, 2022. Nephrologie & Therapeutique can be contacted at: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France. (Elsevier - www.elsevier.com; Nephrologie & Therapeutique - http://www.journals.elsevier.com/nephrologie-and-therapeutique/)

The news editors report that additional information may be obtained by contacting Maxime Raffray, University of Rennes, French School of Public Health (EHESP), REPERES (Recherche en pharmaco-epidemiologie et recours aux soins)-EA 7449, 35000 Rennes, France. Additional authors for this research include Imene Mansouri, Mathilde Lassalle, Florent de Vathaire, Brice Fresneau, Chiraz Fayech, Helene Lazareth, Nadia Haddy, Sahar Bayat and Cecile Couchoud.

Publisher contact information for the journal Nephrologie & Therapeutique is: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France.